NCT00546871View on ClinicalTrials.gov

Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

October 3, 2007

Primary Completion Date

July 1, 2009

Study Completion Date

September 1, 2009

Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
DRUG

Immune Globulin Intravenous (Human), 10%

Intravenous administration in Study Part 1, subcutaneous administration in Study Parts 2 and 3

Trial Locations (9)

Unknown

Los Angeles

Centennial

North Palm Beach

Atlanta

Durham

Cleveland

Dallas

Galveston

Milwaukee

All Listed Sponsors
lead

Baxalta now part of Shire

INDUSTRY

NCT00546871 - Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects | Biotech Hunter | Biotech Hunter